An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Clovis Oncology to Present at the BofA Securities 2022 Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Clovis Oncology (Nasdaq: CLVS) announced that President and CEO Patrick J. Mahaffy will present at the BofA Securities 2022 Healthcare Conference on May 11, 2022, at 10:00 a.m. Pacific time. The event will take place at the Encore hotel in Las Vegas.
A live webcast of the presentation will be accessible via the company’s investor relations page, with a replay available for 30 days post-event. Clovis Oncology focuses on developing innovative anti-cancer agents and diagnostic tools aimed at specific cancer populations.
Positive
None.
Negative
None.
BOULDER, Colo.--(BUSINESS WIRE)--
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its President and Chief Executive Officer, Patrick J. Mahaffy, will present at the BofA Securities 2022 Healthcare Conference on Wednesday, May 11, 2022, at 10:00 a.m. Pacific time. The conference will be held at the Encore hotel in Las Vegas.
A live webcast of the presentation can be accessed through the investor relations section of the Company’s website at www.clovisoncology.com. Following the live presentation, a replay of the webcast will be available on the Company’s website for 30 days.
About Clovis Oncology
Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the US, Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops, with partners, diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use. Clovis Oncology is headquartered in Boulder, Colorado; please visit www.clovisoncology.com for more information, including additional office locations in the US and Europe.